2021
SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation
Jarlhelt I, Nielsen S, Jahn C, Hansen C, Pérez-Alós L, Rosbjerg A, Bayarri-Olmos R, Skjoedt M, Garred P. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation. Frontiers In Immunology 2021, 12: 767981. PMID: 34804055, PMCID: PMC8596567, DOI: 10.3389/fimmu.2021.767981.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific antibodiesSARS-CoV-2 receptor-binding domainReceptor-binding domainComplement activationAntibody responseInflammatory responseSARS-CoV-2 antibody responseDisease severitySevere acute respiratory syndrome coronavirus 2Fc gamma receptor engagementAcute respiratory syndrome coronavirus 2COVID-19 disease severitySARS-CoV-2 antibodiesSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Pro-inflammatory cytokines TNFAntibody-mediated complement activationProminent complement activationSpecific antibodiesSyndrome coronavirus 2COVID-19 severitySerious public health threatCoronavirus disease 2019Classical complement pathway activationClassical complement activation
2020
Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia
Perez-Diez A, Wong C, Liu X, Mystakelis H, song J, Lu Y, Sheikh V, Bourgeois J, Lisco A, Laidlaw E, Cudrici C, Zhu C, Li Q, Freeman A, Williamson P, Anderson M, Roby G, Tsang J, Siegel R, Sereti I. Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia. Journal Of Clinical Investigation 2020, 130: 5326-5337. PMID: 32634122, PMCID: PMC7524466, DOI: 10.1172/jci136254.Peer-Reviewed Original ResearchConceptsAb-dependent cell-mediated cytotoxicityComplement-dependent cytotoxicityT cellsCD4 lymphopeniaICL patientsWhole cohortIdiopathic CD4 lymphopeniaLysis of CD4Multitude of autoantibodiesCell-mediated cytotoxicityNovel therapeutic targetPathogenicity of autoantibodiesClassical complement activationClassical complement pathwayCausal infectionLow CD4Anti-CD4Opportunistic infectionsAutoimmune diseasesComplement depositionImmune deficiencyConclusionOur dataHigh prevalencePatient seraCD4
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply